GAD2 and nervous system disorder: The toxicity was limited to cytokine release syndrome grade 1.<h4>Discussion</h4>The favorable clinical response observed in our patient, along with other reports demonstrating preliminary efficacy and limited toxicity, supports further study of CD19 CAR-T cell therapy in GAD65 neurological disorders.